Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe practical decision: GLP-1 vs dual agonist tolerability, what the evidence shows
The mechanism difference that actually affects how you feel
Mounjaro (tirzepatide) activates two receptors, GIP and GLP-1. Wegovy (semaglutide) activates GLP-1 only. That distinction matters for tolerability because GIP receptor activity may influence how the gut handles the slowdown in gastric emptying. Some people find the dual pathway sits better with their digestive system at lower doses; others find GLP-1 stimulation alone more predictable. Neither medicine avoids GI effects, they are baked into the mechanism.
The core side-effect list is strikingly similar across both: nausea is the most commonly reported, followed by constipation, diarrhoea, vomiting, reflux and fatigue. With either medicine, symptoms tend to be sharpest in the first few weeks and after each dose step up, then ease for most people. If you want to dig into the specifics, our detailed look at Wegovy v Mounjaro side effects walks through what each medicine tends to produce and when.
One quick check worth doing in under a minute: scan the side-effects section of whichever medicine's NHS patient page applies to you (NHS tirzepatide guidance for Mounjaro, or the equivalent for Wegovy) so you know the common-versus-rare split before you start.
Where the trial data actually differ, and where they don't
No large head-to-head trial was designed primarily to compare tolerability between these two medicines. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, ran tirzepatide against semaglutide 2.4mg in adults with obesity over 72 weeks and found greater average weight loss with tirzepatide, but it was not powered to declare one safer or better-tolerated than the other. Trial discontinuation rates due to side effects were broadly comparable.
Within each medicine's own programme, the titration schedule is designed specifically to manage tolerability: Mounjaro starts at 2.5mg (a dose chosen to settle the system before therapeutic doses begin), and Wegovy starts at 0.25mg. Both escalate slowly, in roughly four-week steps set by the prescriber. If you are trying to work out whether Wegovy has less side effects than Mounjaro, it is worth knowing that the answer is partly a question of how the dose is managed, not just which molecule is involved.
At higher maintenance doses, some patients report that Mounjaro's 15mg produces stronger appetite suppression with a GI profile they manage well; others find semaglutide's 2.4mg (or the newer 7.2mg option) more predictable. Individual response varies considerably.
The factors a prescriber weighs before choosing between them
When a prescriber at a service like nume reviews your consultation, the side-effect question is one part of a broader assessment. Relevant factors include your history of GI conditions, whether you have type 2 diabetes, your current medicines (for example, tirzepatide can reduce oral contraceptive absorption during the first four weeks of treatment and after each dose increase, which affects what additional contraception you need, see NHS England's guidance on weight-management injections for detail), and your personal preference between injection formats.
Our full Wegovy vs Mounjaro guide also covers how the tolerability picture shifts if you move doses, including why a patient who struggled with nausea on one medicine at a higher dose might not have the same experience on the other, or at a different titration pace. That is a conversation for a prescriber, not a product page.
Side-effect snapshot: Wegovy vs Mounjaro at a glance
| Side effect | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Nausea | Very common (≥1 in 10) | Very common (≥1 in 10) |
| Vomiting | Very common | Very common |
| Diarrhoea | Very common | Very common |
| Constipation | Very common | Very common |
| Injection-site reactions | Common | Common |
| Pancreatitis (rare but serious) | Uncommon; seek urgent help for severe stomach pain radiating to the back | Uncommon; same urgent-help criteria apply |
Figures drawn from respective UK SmPCs and the NHS tirzepatide medicine page. The MHRA issued a specific Drug Safety Update in January 2026 highlighting acute pancreatitis as a known risk with GLP-1 medicines, both Wegovy and Mounjaro are covered by that warning. Report any suspected side effect via the Yellow Card scheme.
Which medicine suits you is a clinical decision our prescribers make with you, not something a comparison table can settle. If you are still weighing up whether Mounjaro or Wegovy has less side effects and would like to explore your options, speak to our prescribers through a free consultation.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.